Table 2.
Treatment Administered
| Parameter | Arm A: PTC | Arm B |
||
|---|---|---|---|---|
| PTC | HTC/FTC | ATC | ||
| No. of patients | 19 | 22 | 11 | 4 |
| Median duration of therapy, months | 14 | 10 | 8 | 2 |
| Range | 0.25-32 | 0.25-33 | 0.25-26 | 0.5-10 |
| Duration of therapy in all patients, months | 262 | 296 | 124 | 16 |
| Therapy, mg/d dose/months | ||||
| 800 | 84 | 186 | 60 | 16 |
| 600 | 90 | 70 | 56 | 0 |
| 400 | 88 | 40 | 8 | 0 |
| No. of patients with dose reduction | 11 | 10 | 8 | 0 |
| Median time to dose reduction, months | 1.5 | 4.5 | 1.7 | NA |
| Range | 1-12 | 0.5-26 | 0.5-9.5 | NA |
| Reasons for dose reduction | ||||
| Hand-foot skin reaction | 6 | 6 | 2 | 0 |
| Diarrhea and weight loss | 2 | 3 | 1 | 0 |
| Hypertension | 2 | 0 | 1 | 0 |
| Fatigue | 1 | 0 | 0 | 0 |
| Arthralgia | 0 | 1 | 1 | 0 |
| Musculoskeletal chest pain | 0 | 0 | 2 | 0 |
| Mouth pain | 0 | 0 | 1 | 0 |
Abbreviations: PTC, papillary thyroid cancer; HTC, Hürthle cell carcinoma; FTC, follicular thyroid cancer; ATC, anaplastic thyroid cancer; NA, not available.